7 March 2022
EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial
Based on recent results from the Recovery trial showing a mortality benefit for baricitinib in severe COVID-19, EU SolidAct has decided to stop inclusion of immunocompetent participants to the baricitinib trial. However, as the safety and benefit of immunomodulators including baricitinib is still not determined in immunocompromised individuals, EU SolidAct will continue to include these individuals, who so far have been neglected in most treatment trials for COVID-19. As the response to vaccination is impaired in immunocompromised individuals, a substantial proportion are still getting severe or persistent symptoms due to current variants of SARS-Cov2, and better treatment options are urgently needed.